Therapeutic Response

PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Paclitaxel in combination with Pembrolizumab in patients with Peritoneal Serous Carcinoma.

Statements

Source and description
Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS >= 1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Keytruda (pembrolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pembrolizumab in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 with a CPS >= 1 and who have received one or two prior systemic treatment regimens.